Ediblez OTC and Rosebuds Cannabis Co.

02/25/2026

🙌🏻🙌🏻💚💚✅✅Ediblez OTC

Supporters of legal recreational ma*****na for adults made another push at the state capitol Tuesday, facing fierce opposition even as the final decision may rest with President Trump.

02/19/2026

And this is why we carry these products! Quality ✅
Minnesota ✅
Ediblez OTC

02/18/2026

Good morning‼️
We have our Microcannabis license ✅
Local approvals ✅
Inventory 🤞🏼🤞🏼 next week!
📍We are celebrating 3+ years as a Small Locally owned business who prides itself on high quality products with knowledgeable staff. 💚
Thank you to all who continue to support us! 🙌🏻
Ediblez OTC

02/15/2026

💚💚💚🙌🏻🙌🏻🙌🏻
Ediblez OTC

Today.....💚💨💨

02/13/2026

One step closer…new sign is up! ✅
Ediblez OTC

02/13/2026

💚 Our best-selling product! Ediblez OTC

Dive into the ingredients and their benefits 🌿✨
📲Follow our page learn more and ehnhance your nuquanna experience 🤩

02/09/2026

We are getting closer and closer to making the full transition to Rosebuds Cannabis Company. Stay Tuned! 💜💚Ediblez OTC

01/29/2026

🙌🏻🙌🏻🙌🏻✅✅✅💚💚💚
Ediblez OTC

Have you spoken to your healthcare provider about switching to cannabis?

01/27/2026

⭐️⭐️⭐️⭐️⭐️
Five Star Review Yesterday!
This made our day!
Folks, we are a locally owned small business doing everything we can to survive and thrive. We don’t burden ourselves with debt that we cannot pay back, we do not just sell products to make money, we choose quality products from reputable wholesalers, we hold ourselves to a certain standard so that all feel welcome in our business. We strive to educate and grow a community. Thank you for on your patience as we make this transition. 💚💚💚
Ediblez OTC

01/20/2026

Ediblez OTC

Recent research, particularly a small but rigorous clinical trial from Brazil published in the Journal of Alzheimer’s Disease, indicates that microdosing cannabis extract holds promise for slowing cognitive decline in patients with mild Alzheimer’s disease.

This phase 2 randomized, double-blind, placebo-controlled study involved elderly participants aged 60 to 80 who received very low daily oral doses of a balanced THC-CBD extract—approximately 0.35 mg THC and 0.245 mg CBD—for 26 weeks.

These sub-psychoactive amounts avoid the intoxicating "high" typically linked to higher cannabis use. The primary measure, the Mini-Mental State Examination (MMSE), showed that the cannabis group experienced stabilization in cognitive scores, with a slight mean improvement, while the placebo group declined noticeably.

The between-group difference was about 1.7 points on the 30-point scale, considered clinically meaningful given that untreated Alzheimer’s patients often lose 3 to 4 MMSE points annually. This suggests the low-dose cannabinoids may help preserve cognitive function over time.

Researchers attribute potential benefits to cannabinoids' multi-target effects, including reducing neuroinflammation, combating oxidative stress, modulating the endocannabinoid system (which declines with age and supports neuroprotection), and possibly influencing amyloid plaque clearance or synaptic health—key factors in Alzheimer’s progression.

Earlier case reports, including one tracking a single patient for 22 months on microdoses, also noted cognitive gains without major side effects. The treatment proved safe, with no significant adverse events differing from placebo. However, this remains preliminary due to the small sample size and short duration.

Larger, longer multicenter trials with biomarkers are essential to confirm whether microdosing truly slows disease progression or merely stabilizes symptoms temporarily. While not a cure, these findings offer hope for a novel, low-risk adjunctive approach in managing this devastating condition.